CC‐885, the pioneering GSPT1‐targeting degrader identified from a library of analogs derived from immunomodulatory drug lenalidomide, defined GSPT1 as a CRBN “neosubstrate” specificity on the CRL4CRBN E3 ubiquitin ligase, transforming GSPT1 from an “undruggable” target to an attractive, promising target for the treatment of pan‐cancer (especially for AML). Here, CRBN is linked to cancer.